NuRaX Blog

Parkinson's disease affects more than ten million people worldwide, making it the second most prevalent neurodegenerative disorder after Alzheimer's disease. Characterized by progressive motor symptoms such as tremor, rigidity, bradykinesia (slowness of movement), and postural instability, Parkinson's disease has long posed a formidable challenge for clinicians and patients alike. While dopaminergic medications remain the cornerstone of early-stage management, their efficacy often diminishes over time, giving rise to debilitating motor fluctuations and dyskinesias that dramatically reduce quality of life.

Deep brain stimulation (DBS) has emerged as one of the most significant advances in the treatment of Parkinson's disease over the past three decades. Approved by the FDA in 2002 for the treatment of advanced Parkinson's, DBS offers a powerful surgical intervention that can substantially reduce motor symptoms, decrease medication dependence, and restore meaningful independence to patients whose disease has progressed beyond the reach of pharmacological therapy alone.

What Is Deep Brain Stimulation?

Deep brain stimulation is a neurosurgical procedure in which thin, insulated electrodes are implanted into specific regions of the brain. These electrodes deliver continuous, precisely calibrated electrical impulses to targeted neural circuits, modulating abnormal brain activity that underlies the motor symptoms of Parkinson's disease. A small, battery-powered pulse generator -- often referred to as the neurostimulator -- is implanted beneath the skin near the collarbone, connected to the brain electrodes via thin extension wires that run under the skin of the neck and scalp.

The concept behind DBS is rooted in decades of research into the basal ganglia, a group of interconnected brain structures that play a central role in movement regulation. In Parkinson's disease, the progressive loss of dopamine-producing neurons in the substantia nigra leads to dysfunctional signaling within the basal ganglia circuitry. DBS works by delivering high-frequency electrical stimulation that effectively overrides these aberrant neural signals, restoring more normal patterns of motor control.

How DBS Works: Targeting the Subthalamic Nucleus

The success of DBS depends critically on precise electrode placement. Two primary brain targets are used in Parkinson's disease treatment: the subthalamic nucleus (STN) and the globus pallidus internus (GPi). Of these, the subthalamic nucleus has become the most widely used target due to its central role in the motor circuit and the broad range of benefits associated with its stimulation.

The subthalamic nucleus is a small, lens-shaped structure located deep within the brain, approximately the size of a grain of rice. Despite its diminutive size, it serves as a critical relay station in the indirect pathway of the basal ganglia. In Parkinson's disease, the STN becomes hyperactive due to reduced dopaminergic inhibition, sending excessive excitatory signals that ultimately suppress voluntary movement. By delivering high-frequency stimulation (typically between 130 and 185 hertz) to the STN, DBS effectively dampens this pathological overactivity, allowing motor commands to flow more freely through the basal ganglia circuitry.

DBS does not cure Parkinson's disease or halt its progression, but it can dramatically reduce the motor symptoms that most impair daily functioning, offering patients a quality of life that medication alone can no longer sustain.

Who Is a Candidate for DBS?

Not every person with Parkinson's disease is a suitable candidate for deep brain stimulation. Careful patient selection is one of the most important factors in achieving successful outcomes. At NuRaX Care and Research Center, our multidisciplinary team conducts a thorough evaluation to determine candidacy based on several key criteria:

• Diagnosis of idiopathic Parkinson's disease: DBS is most effective for patients with a confirmed diagnosis of idiopathic (typical) Parkinson's disease. Atypical parkinsonian syndromes, such as progressive supranuclear palsy or multiple system atrophy, generally respond poorly to stimulation.
• Meaningful response to levodopa: Patients who have demonstrated a clear, positive response to levodopa therapy are more likely to benefit from DBS. Symptoms that improve with medication are typically the same symptoms that respond to stimulation.
• Motor fluctuations and dyskinesias: DBS is especially beneficial for patients who experience troublesome "on-off" motor fluctuations or levodopa-induced dyskinesias that cannot be adequately controlled through medication adjustments.
• Medication-resistant tremor: Patients with severe tremor that persists despite optimal pharmacological management are excellent candidates for DBS, as tremor is one of the symptoms most reliably suppressed by stimulation.
• Adequate cognitive function: Patients must be free of significant dementia or severe psychiatric illness, as cognitive impairment can diminish the benefits of DBS and increase the risk of postoperative complications.
• Realistic expectations: Patients and their families must understand that DBS manages symptoms rather than curing the disease, and must be committed to the ongoing programming and follow-up that the therapy requires.

The Surgical Process

The DBS surgical procedure is typically performed in two stages and represents a remarkable feat of precision neurosurgery. At NuRaX, our neurosurgical team utilizes the latest imaging and navigation technologies to ensure the highest standards of safety and accuracy.

Stage One: Electrode Implantation

The first stage involves the implantation of the brain electrodes. Preoperative high-resolution MRI scans are obtained and fused with stereotactic coordinates to create a detailed three-dimensional map of the patient's brain anatomy. On the day of surgery, a lightweight stereotactic frame is affixed to the patient's head to provide the spatial reference points needed for precise electrode targeting.

Through a small burr hole created in the skull, the neurosurgeon advances the electrode along a pre-planned trajectory toward the subthalamic nucleus. In many centers, the patient remains awake during a portion of the procedure to allow real-time electrophysiological monitoring and clinical testing. This intraoperative mapping enables the surgical team to confirm optimal electrode placement by observing the immediate effect of test stimulation on the patient's tremor, rigidity, and movement. Once the ideal position is verified, the electrode is permanently secured.

Stage Two: Pulse Generator Implantation

The second stage, typically performed one to two weeks after electrode implantation, involves placing the neurostimulator (pulse generator) beneath the skin of the upper chest, just below the collarbone. Extension wires are tunneled under the skin to connect the chest-mounted generator to the brain electrodes. This stage is performed under general anesthesia and usually takes approximately one hour. The neurostimulator is a programmable device that can be adjusted by the clinical team to optimize therapeutic benefit while minimizing side effects.

Recovery and Programming

Following DBS surgery, most patients spend one to three days in the hospital for monitoring before being discharged home. The initial recovery period typically spans two to four weeks, during which patients may experience temporary swelling at the surgical sites and mild discomfort that is managed with standard pain medication.

The programming phase begins approximately two to four weeks after the second surgery, once postoperative swelling has subsided. During programming sessions, a trained DBS specialist uses an external programmer to adjust the stimulation parameters -- including amplitude (voltage), pulse width, and frequency -- to find the optimal settings for each individual patient. This process is iterative and may require several sessions over the first few months as the brain adapts to stimulation and as medications are concurrently adjusted.

Patients continue to attend regular follow-up appointments for ongoing programming refinements and battery monitoring. Modern rechargeable neurostimulators can last fifteen years or more, significantly reducing the need for replacement surgeries compared to earlier non-rechargeable devices.

Outcomes: Approximately 90% Improvement in Motor Symptoms

The clinical outcomes of DBS for Parkinson's disease have been extensively documented in large-scale randomized controlled trials and long-term follow-up studies. The evidence consistently demonstrates that DBS produces profound and sustained improvements in motor function:

• Tremor reduction: DBS achieves approximately 90% suppression of Parkinsonian tremor in well-selected candidates, making it one of the most effective treatments available for this debilitating symptom.
• Rigidity and bradykinesia: Muscle stiffness and slowness of movement typically improve by 50 to 70%, restoring the ability to perform daily activities such as dressing, eating, and writing.
• Motor fluctuations: The duration of daily "off" periods -- times when medication is not effectively controlling symptoms -- is reduced by an average of 60 to 70%, providing patients with more consistent motor function throughout the day.
• Dyskinesia reduction: Levodopa-induced involuntary movements are reduced by approximately 60 to 90%, primarily due to the ability to significantly lower medication doses after DBS.
• Medication reduction: On average, patients are able to reduce their dopaminergic medication by 50 to 60% following DBS, decreasing both the cost and the side effects associated with long-term drug therapy.
• Quality of life: Multiple validated quality-of-life measures show significant and sustained improvement following DBS, with benefits persisting for ten years or more in many patients.

Long-term studies have shown that DBS benefits for tremor and rigidity remain robust even a decade after surgery, though the underlying disease continues to progress. The therapy effectively extends the window of high-quality motor function by many years.

Looking Ahead: The Future of DBS at NuRaX

The field of deep brain stimulation continues to evolve rapidly. Next-generation DBS systems are incorporating adaptive or "closed-loop" technology that can sense neural activity in real time and adjust stimulation parameters automatically, moving away from the continuous, fixed-output stimulation used in current devices. Directional leads with segmented electrodes now allow clinicians to steer the electrical field with greater precision, maximizing therapeutic benefit while minimizing stimulation of adjacent structures that can cause side effects.

At NuRaX Care and Research Center, our commitment to advancing neuromodulation therapies extends beyond clinical practice. Our research programs actively investigate novel targets, refined surgical techniques, and emerging technologies that promise to further improve outcomes for patients with Parkinson's disease and other neurological conditions. We believe that every patient deserves access to the most advanced, evidence-based treatments available, and we are dedicated to making that vision a reality.

If you or a loved one is living with Parkinson's disease and current treatments are no longer providing adequate relief, deep brain stimulation may offer a path to significantly improved quality of life. We encourage you to reach out to our team for a comprehensive evaluation and to learn more about whether DBS is right for you.